Revere Pharmaceuticals develops a drug discovery and development platform targeting Rac1 and its genomic variants.
Revere Pharmaceuticals has raised $1.1M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in September 2021.
Revere Pharmaceuticals is headquartered in Arlington, United States.
Revere Pharmaceuticals develops a drug discovery and development platform targeting Rac1 and its genomic variants.
Revere Pharmaceuticals is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Revere Pharmaceuticals — Funding & Investors." VCBacked, September 1, 2021, https://www.vcbacked.co/company/revere-pharmaceuticals. Accessed August 15, 2026.
VCBacked. (2021). Revere Pharmaceuticals — Funding & Investors. Retrieved August 15, 2026, from https://www.vcbacked.co/company/revere-pharmaceuticals
{{cite web |title=Revere Pharmaceuticals — Funding & Investors |url=https://www.vcbacked.co/company/revere-pharmaceuticals |website=VCBacked |access-date=August 15, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated